Introduction

Multiple myeloma is the second most common hematological malignancy worldwide [1,2]. The disease is characterized by a monoclonal expansion of malignant plasma cells (PC) in the bone marrow, committed to the production of a patient-specific monoclonal serum immunoglobulin, the "paraprotein". While many patients initially respond well to PC-directed therapies, some patients relapse and ultimately succumb to the disease [3]. Although the malignant PC clone is held responsible for most myeloma-related morbidity such as anemia, renal failure and bone lesions, it has been a subject of debate whether or not these cells possess enough proliferative potential to sustain the disease. The discovery of (surface) immunoglobulin-positive B cells expressing the same patient-individual variable region immunoglobulin (Ig) rearrangement as the malignant PC clone – so called clonotypic B cells – has therefore fueled speculations about a potential (pre-)malignant B cell compartment with stem cell like properties feeding the malignant PC compartment in multiple myeloma [4,5,6,7,8]. Attempts have been made to use anti-idiotypic antibodies in the detection of B cell populations with clonotypic surface Ig, but their specificity has been limited, since they react with more than one myeloma Ig and also recognize a number of normal B cell clones [9,10]. Molecular detection of potential myeloma precursor B cells has therefore been mainly based on PCR amplification of the patient-specific Ig rearrangement from either peripheral blood or bone marrow-derived DNA or cDNA (mRNA) [11,12,13,14,15,16,17]. To discriminate between contaminating IgG- or IgA-positive PCs and clonotypic B cells, many studies worked on the purified CD19-positive B cell fraction and/or used IgM-specific primers for immunoglobulin gene amplification (although some studies looked at other isotypes as well). The percentage of patients in which myeloma-related Ig-positive clonotypic B cells could be detected ranged between 40% and 87% [15,17,18]. Limiting dilution PCR indicated that in myeloma patients between 0.24% and 25% of peripheral blood mononuclear cells (PBMC) and up to 66% of all peripheral B cells represent clonotypic B cells [15,16,17]. This data implies that a substantial proportion of B cells are clonally related to the malignant PC clone. However, a rather high interpatient and interstudy variability (with some studies suggesting lower percentages of clonotypic B cells [18,19,20]), possibly related to methodical heterogeneity of the PCR technique, as well as potential confounders (unspecific primer annealing or expression of atypical, non-clinical Ig transcripts by myeloma subclones [21]) may limit the validity of such PCR-based approaches. When
looking at different stages of the disease, the estimated frequencies of such clonotypic cells varied between lower levels after chemotherapy and higher levels in relapsed disease [14,15,16, 22,23,24,25]. This data has been interpreted as preliminary evidence that these cells do not merely represent non-malignant clonotypic remnant B cells which had initially produced the malignant plasma cell clone, but supports their role as an active “feeder” in myelomagenesis and myeloma progression. To directly and functionally address the biological significance of this B cell population, peripheral B cells from myeloma patients have been xenotransplanted into immunodeficient mice. These studies produced inconsistent findings [26,27,28,29] [30,31]. Importantly, if the hypothesis of an active B cell “feeder” population holds true, one would expect these B cells to mirror many genetic changes observed in the malignant PC compartment. Towards this end, several studies have compared the genetic lesions in PCs with those in the peripheral B cell compartment, supporting a model of intraclonal evolution at the PC level [32,33,34,35,36,37,38]. More evidence questioning the role of clonotypic B cells as “feeders” of the malignant PC compartment came from a recent study on the clonal hierarchy in light-chain myeloma [38] and from the analysis of class switch recombination from IgM to IgG or IgA in multiple myeloma [39].

Taken together, the concept of (pre-)malignant surface Ig-positive clonotypic B cells feeding the malignant PC compartment in a stem cell like manner is still highly controversial. One of the major problems hampering scientific progress can be ascribed to the fact that clonotypic B cells have been only detectable by PCR so far. Besides general concerns regarding this approach as indicated above, a major drawback of PCR-based methods is that the cells of interest cannot be morphologically identified or even directly isolated for further analyses to determine their biological role.

To overcome this critical challenge irrespective of the controversy on the functional relevance of conotypic cells in myeloma, we set out to develop a tool to specifically detect and isolate these cells for exact quantification and to obtain the possibility of their further functional characterization in future studies. Therefore, we established patient-individual ligands mimicking the epitope recognized by the myeloma immunoglobulin to specifically target clonotypic surface Ig-positive B cells from myeloma patients. Our analysis of 15 myeloma patients indicates, that clonotypic B cells are a very rare event in myeloma and that their absolute numbers and relative frequencies have been significantly overestimated by indirect PCR-based quantification. This study, as a matter of fact, does not provide evidence to reject the “feeder” B cell hypothesis. However, the limited percentage of patients with PCR-detectable and ligand-detectable clonotypic B cells challenges the concept of an active pre-switch B cell “feeder” compartment as a general principle and indispensable prerequisite for myeloma pathogenesis and progression.

**Table 1. Clinical characteristics of myeloma patients.***

| Patient Code | Diagnosis | Date of clinical sample acquisition | Treatment | Remission status (at date of sample acquisition) |
|--------------|-----------|------------------------------------|-----------|-----------------------------------------------|
| MM001        | MM        | 06/2003 06/2003 and 07/2008        | autologous stem cell transplant (11/2004), idiotype vaccination (06-11/2005), lenalidomide maintenance (08/2006-02/2007), lenalidomide/dexamethasone (03/2008-07/2008) | PR/SD |
| MM003        | MM        | 02/2002 02/2002                    | autologous stem cell transplant (05/2003), thalidomide maintenance, bortezomib (02-04/2005), idiotype vaccination (06-11/2005), cyclophosphamide/bortezomib/dexamethasone (02-07/2006) | active disease |
| MM008        | MM        | 03/2005 03/2005                    | autologous stem cell transplant (11/2005), allogeneic stem cell transplant (02/2006) | active disease |
| MM020        | MM        | 05/2005 05/2005 and 09/2008        | autologous stem cell transplant (11/2005), idiotype vaccination (08/2006-09/2008) | PR |
| MM021        | MM        | 09/2000 05/2009                    | autologous stem cell transplant (11/2001 and 07/2007), lenalidomide/ dexamethasone (07-12/2008), bortezomib/dexamethasone (05/2009) | PD |
| MM022        | MM        | 05/2004 05/2009                    | autologous stem cell transplant (12/2005), bortezomib/dexamethasone (12/2006-08/2007), lenalidomide/dexamethasone (01-09/2008), thalidomide/bortezomib/dexamethasone (10/2008-02/2009), allogeneic stem cell transplant (02/2009) | PD |
| MM023        | MM        | 12/2008 03/2009                    | bortezomib/dexamethasone (01-03/2009) | PR |
| MM025        | MM        | 09/2005 08/2009                    | autologous stem cell transplant (11/2005 and 01/2006), bortezomib/dexamethasone (07-08/2009) | PD |
| MM026        | MM        | 08/2009 08/2009                    | -         | active disease |
| MM031        | MM        | 11/2007 04/2010                    | bortezomib/dexamethasone (12/2007-01/2008), autologous stem cell transplant (05/2008 and 08/2008), bortezomib maintenance | PD |
| MM032        | MM        | 01/2011 01/2011                    | autologous stem cell transplant (06/2011 and 09/2011) | active disease |
| MM034        | MM        | 02/2011 02/2011                    | -         | active disease |
| MM036        | MM        | 2007 02/2011                       | bortezomib (01/2011) | PR |
| MM048        | MM        | 03/2011 03/2011                    | autologous stem cell transplant (09/2011) | active disease |
| MM050        | MM        | 01/2003 04/2011                    | intermittent lenalidomide (01/2003-04/2011), bortezomib/dexamethasone (04-08/2011) | PD |

*MM = multiple myeloma, PR = partial remission, SD = stable disease, PD = progressive disease.

doi:10.1371/journal.pone.0031998.t001
A

**IgG/IgA PCR (detection of PC Ig rearrangement)**

1. **1st PCR**
   - VH family-specific forward leader primer
   - HCDR3 forward primer
   - IgG/IgA reverse primer

2. **2nd PCR**
   - Variable region VH (350-400 bp)
   - Constant region CH

**IgM PCR (detection of clonotypic B cells)**

1. **1st PCR**
   - VH family-specific forward leader primer
   - HCDR3 forward primer
   - IgM reverse primer

2. **2nd PCR**
   - Variable region VH (350-400 bp)
   - Constant region CH

---

B

**MM021**

| IgG PCR (BM) | IgM PCR (PBMC) | IgM PCR (BMMNC) |
|--------------|----------------|-----------------|
| H2O          | H2O            | clonotypic Ig rearrangement |
| 1st PCR      | 2nd PCR        |                 |

**MM025**

| IgG PCR (BM) | IgM PCR (PBMC) | IgM PCR (BMMNC) |
|--------------|----------------|-----------------|
| H2O          | H2O            | clonotypic Ig rearrangement |
| 1st PCR      | 2nd PCR        |                 |

**MM036**

| IgG PCR (BM) | IgM PCR (PBMC) | IgM PCR (BMMNC) |
|--------------|----------------|-----------------|
| H2O          | H2O            | clonotypic Ig rearrangement |
| 1st PCR      | 2nd PCR        |                 |
Materials and Methods

Ethics statement

Blood samples of myeloma patients visiting the Freiburg and Hamburg Medical Centers’ outpatient units were obtained after informed written consent. This study was specifically approved by the institutional review board of the University of Freiburg and the Physician’s Association in Hamburg. Control cells were obtained from healthy donors (HD). Residual bone marrow obtained for routine clinical testing was banked after completion of diagnostic procedures and used for this study after informed consent.

Patients’ characteristics

A total of 15 myeloma patients were included in this study. Table 1 summarizes the clinical characteristics, including first diagnosis, treatment and remission status at the time of sample collection.

Preparation of clinical samples and immunoglobulin purification

Peripheral blood mononuclear cells (PBMC) were isolated from the blood of myeloma patients by Ficoll density gradient centrifugation (Biacoll, Biochrom AG, Berlin, Germany). Viable PBMCs were resuspended in 90% fetal calf serum (FCS) and 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen until use for subsequent FACS analysis, RNA preparation (Roboklon Kit, Roboklon, Berlin, Germany) and cDNA generation (Omniscript® RT Kit by Qiagen, Hilden, Germany). The remaining serum was used for Ig purification by protein-A sepharose (GE Healthcare, Buckinghamshire, UK) for IgG paraproteins and Jacalin (Pierce, Rockford, Illinois) for IgA paraproteins as described by the supplier. Bone marrow samples collected from myeloma patients were treated with a lysis buffer (155 mM ammonium chloride, 10 mM potassium hydrogen carbonate and 1 mM ethylenediaminetetraacetic acid) to eliminate erythrocytes. The bone marrow mononuclear cells (BMMNCs) were resuspended in 90% FCS and 10% DMSO, stored in liquid nitrogen and used for the same applications as described for PBMCs. The Burkitt’s lymphoma cell line CA46 (ATCC #CRL-1648™) and PBMCs from a CLL patient (CLL024), isolated by Ficoll density gradient centrifugation and containing more than 90% monoclonal B cells, were included as controls.

Sequencing of immunoglobulin variable regions of malignant plasma cell clones

To amplify Ig variable heavy and light chain genes from bone marrow, cDNA of myeloma patients, polymerase chain reactions (PCR) were performed with family-specific degenerated leader primers and the corresponding reverse primer either designed for the kappa or lambda light chain constant region or for the IgG or IgA heavy chain constant region (Table S1). PCR products of correct size were excised from agarose gels, purified (HiYield® PCR Clean-up/Gel Extraction Kit by SLG, Gauting, Germany) and subcloned into pJet1.2 cloning vector (Fermentas, St. Leon-Rot, Germany) according to the manufacturer’s instructions. A minimum of eight clones were sequenced per variable region (Seqlab, Göttingen, Germany).

Detection of IgM-positive clonotypic B cells by semi-nested PCR

For detection of IgM-positive clonotypic B cells from peripheral blood and bone marrow, a semi-nested PCR approach was established as illustrated in Figure 1A. Therefore, unless indicated otherwise, patient-specific heavy chain complementarity determining region 3 (HCDR3) forward primers were designed (Table S1). As a positive control and in order to test the individual HCDR3 primers, the PC’s Ig rearrangement was amplified by semi-nested PCR from BMMNC cDNA (1st PCR: family-specific forward primer + IgG (or IgA, respectively) reverse primer, 2nd PCR: HCDR3 forward primer + IgG (or IgA, respectively) reverse primer; Figure 1A, upper panel, and Figure 1B, left panels). To detect IgM-positive clonotypic B cells from PBMC- or BMMNC-derived cDNA, the IgG/IgA heavy chain reverse primer was replaced by an IgM reverse primer (Figure 1A, lower panel, and Figure 1B middle and right panels). PCR products were electrophoresed in agarose gels and visualized by ethidium bromide staining.

Recombinant expression of myeloma Ig

cDNAs from primary myeloma cells of patients MM001, MM003, MM008 and MM020 were prepared and Fab fragments containing the variable heavy and light chain regions of the respective myeloma Ig were produced commercially (CellGenix, Freiburg, Germany) as described previously [40,41]. Fab fragments were purified by His-tag affinity chromatography. The Ig of myeloma patient MM021, CLL patient 024 and of the Burkitt’s lymphoma cell line CA46 were cloned into the plasmid pBUD, expressed as IgG1 antibody in HEK293T cells and purified by protein-A affinity chromatography [42].

Random phage display peptide libraries

Four random phage display peptide libraries were used: three linear (X7, X12, X18) and one beta-sheet conformation (X4CX6CX4) (G = cysteine; X = random amino acid). The X12 library was purchased from New England Biolabs (Frankfurt, Germany) and processed as recommended by the manufacturer. All other libraries were generated as described previously [43,44,45,46,47,48,49].

Phage library selection

The libraries were screened on recombinantly expressed myeloma Ig or purified paraprotein as previously described [30,51] after a two-fold negative selection on polyclonal human Ig (Octapharma, Lachen, Switzerland). Random clones from the third or fourth panning round were sequenced (Seqlab, Göttingen, Germany).

Single clone phage binding

Phage clones (10^8 transducing units [TU]) were incubated on myeloma Ig (Fab or purified paraprotein) and control Ig. Bound

Figure 1. Detection of clonotypic Ig rearrangements by semi-nested PCR. A: Illustration of semi-nested PCR approach for the detection of clonotypic Ig rearrangements. Ig genes were amplified using VH family-specific forward leader primers and constant region specific reverse primers (1st PCR). A secondary PCR was used to specifically amplify the clonotypic Ig rearrangement with a patient-individual HCDR3-specific primer. PC = plasma cell, Ig = immunoglobulin, VH = heavy chain variable region, CH = heavy chain constant region, HCDR3 = heavy chain complementarity determining region 3. B: Detection of clonotypic Ig-rearrangements in myeloma PBMCs and BMMNCs of patients MM021, MM025 and MM036. Semi-nested PCRs were performed as described in A. PCR products were loaded on agarose gels stained with ethidium bromide. MM = Multiple Myeloma, PBMC = peripheral blood mononuclear cell, BMMNC = bone marrow mononuclear cell.

doi:10.1371/journal.pone.0031998.g001
phage were either quantified by ELISA as suggested by the NEB phage display manual or – more accurately – based on E. coli K91kan or ER2738 (for X12 phage) bacterial infection [43,50,51].

GST-fusion protein and competition assays

The oligonucleotide encoding the phage-derived peptide FLNGCDKEDWMCWVTT was digested with BamHI and EcoRI, and cloned into pGEX-2TK (Amersham, Buckinghamshire, UK). Proteins were expressed in E. coli BL21 (Invitrogen, Camarillo, California) and purified according to the manufacturer’s instructions. Competition experiments were done with GST-fusion proteins as described [50].

Detection of surface Ig-positive clonotypic B cells by immunofluorescence using patient-individual ligands

Myeloma patients’ PBMCs, the Burkitt’s lymphoma cell line CA46 and primary CLL cells (CLL024) and were incubated with a 100-fold excess of phage binding selectively to the respective patient’s or cell line’s Ig for 10 minutes on ice. Insertless fd tet and random insert phage YMTPPLSSQQKS (from X12 library) were used as control phage for all experiments.

Table 3. PCR-detection of clonotypic B cells in myeloma patients.*

| MM patient | MM 001 | MM 003 | MM 008 | MM 020 | MM 021 | MM 022 | MM 023 | MM 025 | MM 026 | MM 031 | MM 032 | MM 034 | MM 036 | MM 048 | MM 050 |
|------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| PB         |       | n.e.  |       |       |       | +     |       |       |       | +     | +     | +     |       | +     | +     |
| BM         | n.e.  | n.e.  | n.e.  |       | +     |       |       |       | +     | +     |       | +     | +     |       | +     |

*M= multiple myeloma, PB = peripheral blood, BM = bone marrow, n.e. = not evaluated due to lack of material.

doi:10.1371/journal.pone.0031998.t003
Figure 2. Selection of specific phage-displayed peptide ligands binding to myeloma Ig. A: Enrichment of selectively binding phage on MM021 paraprotein over three selection rounds. A X14 randomized peptide phage display library was screened on immobilized MM021 paraprotein. Bound phage were recovered by K91 bacterial infection, amplified overnight, purified and subjected to the next selection round. Negative preselection of the library was performed in selection round two and three. The selected phage were tested for binding to MM021 paraprotein and the control human polyclonal IgG after each selection round. Bacteria transduced by recovered phage were grown on LB plates containing tetracycline to determine the number of transducing units (TU) by colony counting. Ig = immunoglobulin, MM = Multiple Myeloma. B: Phage selected on myeloma Ig specifically bind the antibody on which they were selected. Examplarily, binding of paraprotein MM021-selected phage FLNGCDKEDWMWVTT and control phage fd tet to MM021 monoclonal antibody, MM021 paraprotein and control human IgG is shown. Bound phage were quantified by Enzyme-linked Immunosorbent Assay (ELISA). Data are shown as means from triplicate experiments (± SEM). C: The
Results

Detection of IgM-positive clonotypic B cells by PCR

15 myeloma patients with different clinical features were included in this study (Table 1). The variable heavy (VH) and variable light (VL) chain Ig rearrangement of the malignant PC clone was amplified using family- and isotype-specific primer pairs (Table S1) and sequenced as described in the Methods section. Table 2 lists the myeloma patients’ Ig isotype, VH and VL gene usage and complementarity determining region 3 (CDR3) as well as the mutational status of the VH and VL chain.

PCR-based approaches to detect clonotypic B cells may be prone to different kinds of errors as described in the introduction section and may therefore not be able to predict the presence or absence as well as the frequency of these potential myeloma precursor cells. However, in an attempt to compare our patient cohort to the cohorts of other studies, we used a PCR protocol similar to what was used by other investigators to screen PBMC and BMMNC for Ig-positive clonotypic B cells. As previously published work most commonly analyzed IgM-isotype expressing clonotypic cells, a semi-nested PCR approach with VHDR3- and IgM-specific primers was established as illustrated in Figure 1A. Figure 1B shows semi-nested PCR reactions for three exemplary myeloma patients. Whereas patient MM021 and MM025 had clear evidence of clonotypic B cells in peripheral blood and bone marrow (Figure 1B, upper and middle panel), in patient MM036 no specific PCR products could be amplified, suggesting the absence of clonotypic B cells in peripheral blood and bone marrow of this patient (Figure 1B, bottom panel). Of all evaluable patients, 50% exhibited clonotypic cells in the peripheral blood as evidenced by PCR (Table 3). This frequency is in line with data from the literature indicating that 40%–87% of myeloma patients show evidence of clonotypic B cells in the peripheral blood by PCR [15,17,18]. In >80% of PCR-positive patients, clonotypic B cells could also be detected in bone marrow (Table 3). However, in this cellular compartment PCR signals were generally weaker, potentially corresponding to the reduced relative frequency of B cells in bone marrow as compared to peripheral blood.

Selection of patient-individual ligands specifically binding to myeloma Ig

After having identified patients with PCR-based evidence of clonotypic B cells in the blood and/or bone marrow, we set out to establish a method allowing us to physically label clonotypic cells in an attempt to precisely quantify and eventually characterize this interesting cellular compartment. We chose the patient-individual clonotypic Ig as cellular target for the development of specific ligands mimicking the epitope recognized by this immunoglobulin. This choice was based on two major reasons: First, clonotypic Ig with its highly patient-individual and tumor-specific paratope region is the most reliable clonal marker of this B cell population. Second, clonotypic Ig is expressed on the surface of B cells, rendering it accessible to our labeling strategy.

We used combinatorial phage display peptide library screenings selecting epitope-mimicking ligands which specifically bind to selected Ig. Peptides were selected from myeloma Igs, irrespective of PCR-based evidence for clonotypic B cells. For the first phage library selections, myeloma Ig was recombantly expressed as IgG-Fab in a prokaryotic system (selections on MM001, MM003, MM008 and MM020). As this recombinant approach is very labor-intensive, we also evaluated naturally occurring IgG or IgA paraproteins purified from serum as a source of target Ig. Paraproteins were purified by protein-A (IgG) or jacalin (IgA) chromatography and purity was assessed by coomassie staining of electrophoretically separated eluted Ig fractions (data not shown). Given that all patients had highly elevated Ig serum levels at the time of sample collection, contamination by non-paraprotein IgG or IgA was deemed negligible. Indeed, in most of the cases, binding phage could be enriched over three to four selection rounds on recombantly expressed Fab as well as on purified paraprotein (exemplarily shown in Figure 2A) with at least one out of four random peptide phage libraries with different insert design (X7, X12, X18 and X18 CX6CX4 = beta-sheet conformation [BS]). In only three out of 15 myeloma cases selections did not yield binding phage, potentially indicating that none of our peptide designs mimics the natural epitope of these antibodies. Table 4 lists the myeloma Igs and the peptide sequences selected thereon. All of the selected phage, but not random insert control phage, bound specifically to the myeloma Ig on which they were selected and not to control Igs, exemplarily shown in Figure 2B for MM021-selected phage FLNGCDKDEDWMCWTT binding to MM021 paraprotein. Phage FLNGCDEDWMCWTT, selected on the paraprotein of patient MM021, also bound to recombantly expressed MM021 monoclonal antibody, providing proof of concept that selections on purified paraprotein yield phage clones selectively binding to the clonotypic Ig and not to potentially contaminating normal serum Ig (Figure 2B). The higher binding level of this phage to MM021 monoclonal antibody probably reflects the higher degree of purity as compared to MM021 paraprotein. Likewise, phage selected on recombantly expressed antibodies bound specifically to the respective patient’s native paraprotein verifying correct folding of the recombinant antibody used as target for phage selections (data not shown). To confirm that the selected phage displayed peptides bind the respective myeloma Ig independently of other phage components, we exemplarily performed competition assays with a GST-fusion protein containing the phage-derived peptide FLNGCDKDEDWMCWTT.
| MM | Lib. X₁ | Lib. X₁₂ | Lib. X₁₈ | Lib. BS |
|----|---------|----------|----------|--------|
| 001² | YPNYEKWSRPFF | GLPIASPEKTYTFPWKLW | | |
| | SNMTLKELMWPF | TFVGAAYRTQWLEQGRFPFH | | |
| 003² | VYWAWMEDLDHAPEFWKI | | | |
| 008² | RTPIFKPAWSRLAYNS | | | |
| | PQDFYRSRFWDAHMYWQ | | | |
| 020² | YKTPYHMQENWV | WYYPDEEAYENFYELWSR | | |
| | QAIFIETSYDMFQFRF | | | |
| 021¹ | DREDYQLSLNLEYLA | FLNGCDKEDWCMVT | | |
| | GSGYSGNRLVAQPATL | | | |
| 022¹ | TDPWSKS | WHICLDERAMCQIKELV | | |
| | WAPFSL | QDQYTDGSKGENTMVCG | | |
| | | GTWVCGRDERTCRSAS | | |
| | | SKVVCYDERCTCRN | | |
| | | MSGRCLEHRATCYFWN | | |
| 023¹ | VIGPSSL | TQARLDMVNYAPSLR | | |
| | YFSPSFH | GILLRSFQFWNKEEMY | GRNICLGLDHCQV | |
| | | RWNEDFPMGIQLKEML | | |
| | | YRLLMVQGIDRHQEMG | | |
| 025¹ | PDDLSSQYIEGSQKQP | SLSPQVWDACGQSAG | | |
| | PLQYPLVTGTTKEGTH | RREECMETVPICDLYF | | |
| | PLQSGSRDKAESKTKWT | GKHLCRPGGLACVMQ | | |
| | PKILSGANKVEGASHGA | | | |
| | GRAGEKMSGDNKIHES | | | |
| | RDQGYRAPYHVGLGARSG | | | |
| 026¹ | | PEQYCCSRWSCQICH | | |
| | | SREVVVWDGLSLVR | | |
| | | LTPCVRWNCMQGL | | |
| | | TPSKPSIRARCQATI | | |
| | | HPILCAMRSRDCAMTV | | |
| | | AQFLSCDLGRVCTRVS | | |
| 031¹ | SEAIQKNSQNEQ | | | |
| | FGQQKTSAGNEE | | | |
| | NGLLHQNAGNE | | | |
| | ALHKTSQGEMDI | | | |
| | AGHPKDSGNEWA | | | |
| 034¹ | ADSSKRCHFNQC | | | |
| | YNTPSTVHLP | | | |
| 036¹ | EPYTPHLQALW | | | |
| | IXRXGLPTDMKK | | | |
| | GещGSKYLRKQ | | | |
| | VDPNARAKWTE | | | |
| | SSAGPEQPRM | | | |
| | YPELPRWFPNY | | | |
which inhibited binding of phage FLNGCDKEDWMCWVTT to MM021 paraprotein in a concentration-dependent manner (Figure 2C). To evaluate our phage clones for cross-reactivity with different myeloma Igs, we performed extensive binding assays as shown for three exemplary phage clones selected on MM021, MM034 and MM036 as well as respective control phage (Figure 2D). These assays suggest that phage clones selected on myeloma Ig bind their respective target in a highly specific manner and do not cross-react with other myeloma Igs or unrelated proteins.

**Immunofluorescence imaging of surface Ig-positive clonotypic myeloma B cells**

Next, we developed an immunofluorescence protocol allowing us to stain clonotypic myeloma B cells from peripheral blood and bone marrow. As such cells do certainly not represent the bulk of PBMCs or BMMNCs, but constitute only a B cell fraction of unknown size, we had to establish our staining protocol using purely monoclonal Bcell systems as positive controls. We therefore chose the Burkitt’s lymphoma cell line CA46 and primary CLL cells from patient 024 (CLL024), both expressing an individual monoclonal surface IgM. As Ig surface density on clonotypic B cells is unknown so far, these two models seemed particularly suited: Whereas the Burkitt’s lymphoma cell line represents a model with high Ig surface density, the CLL model is characterized by extremely low Ig surface expression. The CLL patient’s as well as the Burkitt’s lymphoma’s Ig were recombinantly produced as IgG1 antibodies. Phage displayed peptide ligands were selected targeting the paratope region of the respective monoclonal Igs and subjected to specificity testings as described for the selections on myeloma Igs (Ref. [42] and data not shown). Cells were loaded with the respective selectively binding phage (phage-CA46 for CA46 and phage-CLL024 for CLL024) or control phage, washed, sedimented on slides and cell-bound phage were detected by FITC-labeling. Confocal microscopic imaging revealed bright and specific membrane staining for both cellular systems (green “corona” in Figure 3A and B). CA46 cells stained with phage-CLL024, CLL024 cells stained with phage-CA46 and the control burkitt’s lymphoma cell line DG-75 stained with both phage did not show a FITC-signal (data not shown). These findings served as proof-of-principle that phage selected on patient- and clone-specific IgG can be used to specifically label the clonotypic surface IgM on parental cells. In a next step, we stained myeloma PBMCs with the respective phage clones and control phage to screen the samples for clonotypic B cells. As expected, none of the myeloma samples without PCR-detectable clonotypic B cells showed any phage-positive cells by immunofluorescence imaging (data not shown). Surprisingly, however, even most of the PCR-positive samples showed no evidence of specifically phage-labeled cells (exemplarily shown for MM031 in Figure 3C). These findings suggested that only a very slim percentage of myeloma PBMCs can be considered to express the clonotypic Ig rearrangement of the malignant PC clone. Only PBMCs from patient MM021 showed sparse specifically labeled cells (Figure 3D, white arrows) when stained with the Ig-specific phage FLNGCDKEDWMCWVTT, whereas the control phage fd did not show any staining. To exclude unspecific binding of phage FLNGCDKEDWMCWVTT, unrelated PBMCs of healthy donors were stained with this phage yielding no specific signals (data not shown). However, this technique does not allow to exactly determine the frequency of such cells, this data was complemented by precise flow cytometric quantification.

**Flow cytometry-based detection and quantification of surface Ig-positive clonotypic myeloma B cells**

As for the immunofluorescence experiments, CA46 and CLL024 cells were used as positive controls to establish an appropriate flow cytometric protocol to screen the blood and bone marrow of myeloma patients for clonotypic B cells. The two-color flow cytometry staining protocol could be adopted from the immunofluorescence experiments with minor modifications. Cell-bound phage were stained with fluoresceiniothiocyanate-conjugated secondary detection (denominated as “phage-FITC”), B cells were stained with a CD19 allophycocyanin-conjugated antibody (“CD19-APC”). Under these conditions, CA46 and CLL024 stained cells showed FITC-positive when loaded with their respective specific phage clones (phage-CA46 for CA46 and phage-CLL024 for CLL024) whereas the respective control phage did not show any staining (Figure 4A and B, first two panels). CA46 cells stained with phage-CLL024 and CLL024 cells stained with phage-CA46 did not show a FITC-signal (data not shown). To determine the sensitivity level of this flow cytometry protocol, control phage-stained CA46 cells were then spiked with decreasing amounts of CA46 cells stained with the specifically binding phage CA46 in a 5%, 2.5%, 1%, 0.5%, 0.1%, 0.05% and 0.005% ratio (Figure 4A). The same spiking experiment was carried out for CLL024 with the specifically binding phage-CLL024 (Figure 4B). In both spiking experiments stained cells could be clearly and repeatedly detected down to ratios of 0.1–0.05%, corresponding to a sensitivity level of this flow cytometry protocol of around 10^-3.

In further experiments, PBMCs and BMMNCs of myeloma patients as well as healthy donor control PBMCs were stained with specific and control phage for detection of clonotypic B cells in the myeloma samples. All phage used in these experiments were initially tested for unspecific B cell binding on healthy donor control PBMCs and on a number of unrelated myeloma PBMCs. None of the phage clones showed preferential binding as compared to control phage under these control conditions (data
Tracing Clonotypic B Cells in Multiple Myeloma

A

CA46 + CA46-selected phage -CA46

CA46 + control phage

B

CLL024 + CLL024-selected phage-CLL024

CLL024 + control phage

C

MM031 + MM031-selected phage AGHPKDSGNEWA

MM031 + control phage

D

MM021 + MM021-selected phage FLNGCDKEDWMCWVTT

MM021 + control phage
not shown). The first two rows of Figure 4C show representative flow cytometric plots of patients MM031 and MM034 after B cell gating. Like these two exemplary patients, most other patients’ PBMCs and all BMMNCs were negative for clonotypic B cells by flow cytometry. This further corroborates the immunofluorescence imaging data, indicating that the absolute number as well as the relative percentage of clonotypic B cells may be very low in the majority of myeloma patients. Based on the previously established sensitivity level of this assay, the frequency of clonotypic B cells is less than one clonotypic B cell per 1000 PBMCs in most myeloma patients. Only PBMCs of patient MM021 exhibited detectable amounts of clonotypic B cells by flow cytometry in line with the immunofluorescence data described above (Figure 4C, bottom row). These cells accounted for about 0.15% of PBMCs and 5% of B cells in this patient. In view of the capacity of our assay to detect even minute fractions of idiotype expressing cells by the epitope-mimicking phage, these data show that the actual number of clonotypic cells is exceedingly low (presumably below the assay’s detection limit of 10^-3 cells in the majority of samples, even if PCR suggests their presence).

**Discussion**

Clonotypic B cells and their biological significance in multiple myeloma are controversially discussed. While many groups have reproducibly identified Ig-positive B cells expressing the same clonal Ig rearrangement as the malignant PC in about 40–87% of myeloma patients, their proportion relative to normal PBMCs and their potential role in the initiation, relapse and progression of multiple myeloma remains largely unclear [15,17,18]. A major limitation to solve this controversy has been the impossibility to morphologically identify or directly isolate these clonotypic cells for further functional analyses to determine their biological role.

Here, we present a technique to phenotypically detect, quantify and isolate clonotypic myeloma B cells by flow cytometry by means of epitope-mimicking ligands highly specific for binding to myeloma-idiotype surface immunoglobulin, independently of Ig isotype. Our cohort comprised 15 patients with confirmed multiple myeloma at different disease stages. Fifty percent of informative patients showed evidence of clonotypic B cells in peripheral blood and/or bone marrow by semi-nested PCR using HCDR3-specific patient-individual primers, in line with published data. Surprisingly, in most patients with PCR-positivity for clonotypic B cells, the number and relative proportion of such cells was below the sensitivity level of our flow cytometry protocol. This sensitivity level had precisely been determined by spiking experiments using two different monoclonal B cell systems with different Ig receptor density (Burkitt’s lymphoma CA46 and CLL024) to reliably range around 10^-3. This indicates that in the majority of myeloma patients, less than one out of 1000 PBMCs or BMMNCs corresponds to a clonotypic B cell. Only one patient of our cohort had detectable amounts of clonotypic B cells by flow cytometry and immunofluorescence imaging, accounting for about 0.15% of PBMCs and 5% of B cells. These findings clearly contradict the estimates of 0.24%–25% of PBMCs and up to two thirds of B cells suggested to be clonotypic B cells by previously published limited dilution PCR assays [15,16,17]. Although for the time being there is no definitive explanation for this unexpected discrepancy, the qualitative detection of clonotypic B cells by semi-nested PCR could be flawed for example by unspecific annealing of the CDR3-primer. Such unspecific annealing may seem implausible at first glance as this immunoglobulin region represents the most variable part of the antibody. However, the diversity in this region is created in part by reading frame shifts, which result in different amino acid sequences, whereas the DNA sequence can be similar or even identical in different antibody clones. This would allow for primer annealing in antibody clones with different CDR3 amino acid sequences giving rise to false positive PCR results and potentially to an overestimation of the frequency of clonotypic B cells by PCR-based approaches.

From the first description of clonotypic B cell Ig rearrangements in 1993 [Ref. [11]] until today, there has been much debate about the biological significance of clonotypic B cells in myeloma as outlined in the introduction section of this manuscript. Animal models ascribing proliferative potential exclusively to clonotypic B cells and the estimated frequency of such cells in remission and relapse have supported the hypothesis that clonotypic B cells may continuously replenish the tumor compartment as “feeder” cells [14,15,16,22,23,24,26,27,28,29]. On the other hand, alternative animal models and recent genetic analyzes of clonal hierarchies as well as class switch recombination events in the B cell lineage of multiple myeloma patients challenge the myeloma stem cell hypothesis [30,31,33,35,37,38,39]. The prominent role assumed by clonotypic B cells over the past years of myeloma research has probably – amongst other factors – to do with the surprisingly high percentages of such cells found by PCR-based quantification. If clonotypic B cells on average constituted about two thirds of all B cells in myeloma patients and if they remained constant or even increased over the course of the disease, they would have to have a survival advantage compared to normal B cells. Either this survival advantage would reflect a (pre-) malignant state of such B cells or – although less likely – clonotypic B cell survival and proliferation would have to be driven by some external signal, e.g. a persisting, non-eliminated antigen that had selected the B cell clone in the first place. Both hypotheses, particularly the first one, would be highly compatible with a “feeder” function of clonotypic B cells. On the other hand, much lower levels of clonotypic B cells, as suggested by our study, do not necessarily contradict these hypotheses and especially do not exclude a causal role of these cells as progenitor cells in disease progression. It should be pointed out, however, that only a limited percentage
of myeloma patients do have PCR-based evidence of B cells clonally related to the malignant plasma cell clone (50% in our study) and even in PCR-positive patients, clonotypic B cells seem to be a very rare event according to our data. Therefore, it seems rather implausible that a clonotypic B cell compartment is an indispensable “feeder” of the malignant PC compartment and an essential prerequisite of myeloma maintenance and progression. Given the apparent rarity of clonotypic B cells in myeloma, it is conceivable that these cells are non-malignant remnants, which may have initially given rise to the malignant plasma cell clone, but which do not have any significance in tumor maintenance. Taking into account the long term persistence of such B cell clones over the course of the disease, they may in fact resemble long-lived memory B cells with some sort of self-renewing properties.

Detection of clonotypic B cells in this study as well as in others has been limited so far to the peripheral blood and bone marrow. This choice has certainly not been made merely for scientific interest, but primarily because these cellular compartments are easily accessible in myeloma patients. However, to get a more comprehensive picture about clonotypic B cells in multiple myeloma, it may be of interest to study other lymphatic tissues, such as spleen or lymph nodes to exclude that these organs possibly serve as niches harboring clonotypic B cells. Our established flow cytometry protocol may serve as a tool to quantitate clonogenic B cells also from different lymphoid organs.

References

1. Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111: 2962–2972.
2. Kyle RA, Rajkumar SV (2009) Multiple myeloma. N Engl J Med 351: 1860–1873.
3. Turesson I, Velez R, Kristinsson SY, Landgren O (2010) Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 28: 830–834.
4. Brennan SK, Matsui W (2009) Cancer stem cells: controversies in multiple myeloma. J Mol Med (Berl) 1079–1085.
5. Huff CA, Matsui W (2008) Multiple myeloma cancer stem cells. J Clin Oncol 26: 2905–2909.
6. Ghosh N, Matsui W (2009) Cancer stem cells in multiple myeloma. Cancer Lett 277: 1–7.
7. Basak GW, Carrier E (2010) The search for multiple myeloma stem cells: the long and winding road. Biol Blood Marrow Transplant 16: 587–594.
8. Pilaris LM, Maselli-Smith A, Szczepak A, Mant MJ, Belch AR (1996) Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Leuk Lymphoma 22: 375–383.
9. Berenson JR, Lichtenstein A, Hart S, Palomares D, Miller RA (1990) Expression of shared idiotypes by paraproteins from patients with multiple myeloma and monoclonal gammapathy of undetermined significance. Blood 75: 2107–2111.
10. Kiyotaki M, Cooper MD, Bertoli LF, Kearney JF, Kubagawa H (1987) Monoclonal anti-Id antibodies react with various properties of human B lineage cells. J Immunol 130: 4130–4138.
11. Corradini P, Boccadoro M, Voena C, Fileri A (1993) Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin IgG- and IgA-ascertaining multiple myelomas. J Exp Med 178: 1091–1096.
12. Corradini P, Voena C, Omeed P, Astolfi M, Boccadoro M, et al. (1993) Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia 7: 1079-1082.
13. Billadeau D, Ahmann G, Greipp P, Van Ness B (1993) The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 178: 1023–1031.
14. Bergagel PL, Smith AM, Szczepak A, Mant MJ, Belch AR, et al. (1995) In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD15, CD56, and monotypic Ig light chain. Blood 85: 436–447.
15. Billadeau D, Van Ness B, Kindilinger T, Kyle RA, Therneau TM, et al. (1996) Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammapathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 88: 289–296.
16. Szczepak AJ, Seegerber K, Wiznia J, Mant MJ, Belch AR, et al. (1998) A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 92: 2841–2855.
17. Taylor BJ, Pittman JA, Seegerber K, Mant MJ, Reiman T, et al. (2002) Intracranial homogeneity of clonotypic immunoglobulin M and diversity of nonclinical post-switch isotypes in multiple myeloma: insights into the evolution of the myeloma clone. Clin Cancer Res 8: 502–513.
18. Chen BJ, Epstein J (1996) Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood 87: 1972–1976.
19. Brown R, Luo XF, Gibson J, Morley A, Sykes P, et al. (1995) Idiotypic oligonucleotide probes to detect myeloma cells by mRNA in situ hybridization. Br J Haematol 90: 113–118.
20. Joshua DE, Brown RD, Luo XF, Gibson J (1996) Circulating clonal lymphocytes in myeloma determined by mRNA in situ hybridization. Blood 88: 1125.
21. Bakke MH, Assingh K, Vanderkerken K, Hagemeier K, et al. (2001) Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour. Leukemia 15: 1127–1132.
22. Rasmussen T, Jensen L, Honore L, Johnsen HE (2000) Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma. Blood 96: 4357–4359.
23. Rottenburger C, Kai K, Bosing T, Cremer FW, Moldenhauer G, et al. (1999) Clonotypic CD20 for multiple myeloma. Blood 96: 4357–4359.
24. Pilarski LM, Mant MJ, Belch AR (1999) Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone. Leuk Lymphoma 32: 199–210.
25. Karl K, Cremer FW, Rottenburger C, Kallmeyer C, Elbrecht E, et al. (1999) Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplant 23: 1019–1027.
26. Pilarski LM, Huppersen G, Seeberger K, Pruski E, Coupland RW, et al. (2000) Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood: 1056–1065.
27. Pilarski LM, Seeberger K, Coupland RW, Edpeter A, Keats JJ, et al. (2002) Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol 30: 221–228.
28. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, et al. (2004) Characterization of clonogenic multiple myeloma cells. Blood: 1033–1036.
29. Matsui W, Wang Q, Barber JP, Berman S, Smith BD, et al. (2000) Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 68: 190–197.
30. Yata K, Yaccoby S (2004) The SCID-rab model: a novel in vivo system for the study of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma. Leukemia 15: 1127–1132.
31. Taylor BJ, Kriangkum J, Pittman JA, Mant MJ, Reiman T, et al. (2008) Analysis of clonotypic switch junctions reveals myeloma subclones that originate from a single class switch event with ongoing mutation in the isotype-switched progeny. Blood 112: 1894–1903.
32. Miceli-Tregnago S, Finzi L, Heiring-Mikesch K, Pfeifer D, et al. (2006) Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli. Eur J Haematol 77: 395–402.
33. Osterreith F, Alkan O, Mackensen A, Lendemann A, Fisch P, et al. (1999) Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination. J Immunol Methods 229: 141–153.
34. Wehr G, Muller F, Schuler J, Tomann T, Nitschke P, et al. (2011) Antitumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model. Int J Cancer.
35. Jager S, Jahnke A, Wilmes T, Adebahr S, Vogtle FN, et al. (2007) Leukemia-targeting ligands isolated from phage-display peptide libraries. Leukemia 21: 411–420.
36. Trepel M, Arap W, Pasqualini R (2001) Modulation of the immune response by systemic targeting of antigens to lymph nodes. Cancer Research 61: 8110–8112.
37. Trepel M, Arap W, Pasqualini R (2002) In vivo phage display and vascular heterogeneity: implications for targeted medicine. Current Opinion in Chemical Biology 6: 399–404.
38. Smith GP, Scott JK (1993) Libraries of peptides and proteins displayed on filamentous phage. Methods in Enzymology 217: 229–257.
39. Muller OJ, Kass F, Weitzman MD, Pasqualini R, Arap W, et al. (2003) Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nature Biotechnology 21: 1040–1046.
40. Michelfelder S, Lee MK, delima-Hahn E, Wilmes T, Kass F, et al. (2007) Vectors selected from adenovirus-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp Hematol 35: 1766–1776.
41. Michelfelder S, Kohlshchter J, Skorupa A, Pfeifer D, Muller O, et al. (2009) Successful expansion but not complete restriction of tropism of adenovirus-associated virus by in vivo biopanning of random virus display Peptide libraries. PLoS One 4: e5122.
42. Binder M, Otto F, Mertelmann R, Veelken H, Trepel M (2006) The epitope recognized by rituximab. Blood: 1973–1978.
43. Binder M, Vogtle FN, Michelfelder S, Muller F, Iblerhaus G, et al. (2007) Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res 67: 3518–3523.